G-CSF to help women with unexplained recurrent miscarriages
Official title: A Randomised, Double Blind, Placebo-controlled Study to Evaluate the Efficacy of Recombinant Human G-CSF in Women With Unexplained Recurrent Miscarriage After IVF With PGT-A Screened Euploid Embryo Transfer
Run by Fakih IVF Fertility Center · NCT07724405 · Data updated 2026-11-12
This study tests whether recombinant G-CSF can help women with two or more unexplained miscarriages who are undergoing IVF with tested embryos.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 44 Years |
| Sex | Women only |
| Enrollment | 150 (estimated) |
| Sponsor | Fakih IVF Fertility Center Academic / other |
| Locations | 1 site (Abu Dhabi) |
| Status | Recruiting |
| Started | July 10, 2026 |
| Main results expected | August 10, 2027 |
| Study ends | October 10, 2027 |
| Registry record updated | July 24, 2026 |
| Trial ID | NCT07724405 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are women 18–44 with ≥2 unexplained miscarriages, undergoing IVF with PGT-A, and meeting BMI and health criteria.
✕Probably not a fit
Patients with identifiable causes of miscarriage, certain autoimmune or systemic illnesses, or prior G-CSF exposure may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This Phase 2 trial investigates the use of recombinant granulocyte colony-stimulating factor (G-CSF) versus placebo in women with unexplained recurrent pregnancy loss who are undergoing IVF with preimplantation genetic testing (PGT-A). The aim is to see if G-CSF can improve endometrial receptivity and immune tolerance to support successful pregnancy. Participants are adult women aged 18–44 with at least two unexplained losses, meeting specific BMI and health criteria, and not having major exclusion conditions. The study is conducted at Fakih IVF Fertility Centre in Abu Dhabi and uses a placebo-controlled design to evaluate outcomes related to implantation and pregnancy progression.
Why it matters
Potential benefit: If successful, participants may experience higher chances of successful implantation and ongoing pregnancy in the setting of unexplained recurrent miscarriage and IVF.
How similar studies have gone: Previous studies of G-CSF for recurrent pregnancy loss have shown mixed results; larger, controlled trials like this are needed to establish benefit.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion: 1. Women aged 18-44 years 2. ≥2 unexplained pregnancy losses 3. Undergoing IVF with PGT-A tested embryos 4. BMI 19-35 kg/m² 6. Exclusion: 1. Parental karyotype abnormalities 2. Correctable uterine abnormalities 3. Systemic autoimmune disease / thrombophilia 4. Uncontrolled systemic illness (e.g. diabetes, infection) 5. Previous G-CSF therapy 6. Hypersensitivity to rhG-CSF or E. coli proteins 7. HIV, malignancy within 5 years, or severe cardiovascular/respiratory history
Where it's running
-
Fakih IVF Fertility Centre LLC
Abu Dhabi, United Arab Emirates Recruiting
Study contacts
- Study coordinator: Dr. Lamiya Mohiyiddeen, MD, FRCOG
- Email: lamiya.mohiyiddeen@fakihivf.com
- Phone: +971543676002
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Effect of a 21-day comprehensive spa program on female infertility
This study tests whether a 21-day spa treatment can impact hormonal profiles and reproductive outcomes in women ages 20-40 with infertility.
-
Right DLPFC fNIRS neurofeedback for anxiety in women with recurrent pregnancy loss
This trial will see if right dorsolateral prefrontal cortex-targeted fNIRS closed-loop neurofeedback with slow-wave sound cues can reduce anxiety and improve heart-rate regulation in women with recurrent pregnancy loss aged 18–45.
-
Hydroxychloroquine plus levothyroxine for improving live birth in euthyroid women with recurrent pregnancy loss and TPO antibodies
This trial will test whether adding hydroxychloroquine to levothyroxine increases the chance of a live birth for euthyroid women who have thyroid peroxidase antibodies and a history of recurrent pregnancy loss.
-
Interactive support messaging for women with recurrent pregnancy loss
This study tests if a weekly messaging program that offers support and advice can help women who have had multiple pregnancy losses have healthier pregnancies and feel better overall.
-
Registry for patients with recurrent pregnancy loss
This study is collecting information from women who have had multiple pregnancy losses to see how different treatments and care options can help them over time.
-
Using prednisolone to help women with unexplained recurrent miscarriages
This study is testing if taking prednisolone can help women who have had multiple unexplained miscarriages have a successful pregnancy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.